SCHEMBL19687545

SCHEMBL19687545

CCOC(=O)C1=C(COCCN)N(C)C(C)=C(C(=O)OC)C1c1ccccc1Cl

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TBXA2R P21731 3/20 0.66
ADRA1A P35348 3/20 0.66
SLC6A3 Q01959 3/20 0.66
HTR1A P08908 2/20 0.66
ADRA2A P08913 2/20 0.66
CHRM1 P11229 2/20 0.66
DRD1 P21728 2/20 0.66
SLC6A2 P23975 2/20 0.66
OPRM1 P35372 2/20 0.66
DRD3 P35462 2/20 0.66
KCNH2 Q12809 2/20 0.66
ABCB11 O95342 2/20 0.66
ABCB1 P08183 2/20 0.66
ADORA3 P0DMS8 2/20 0.66
ADRB3 P13945 2/20 0.66
OPRK1 P41145 2/20 0.66
SCN5A Q14524 2/20 0.66
KCNK2 O95069 1/20 0.66
ADRB2 P07550 1/20 0.66
DRD2 P14416 1/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5459829 0.86 TBXA2R (0.60) TBXA2RADRA1ASLC6A3HTR1AADRA2A
SCHEMBL6732477 0.84 TBXA2R (0.58) TBXA2RADRA1ASLC6A3HTR1AADRA2A
SCHEMBL28403562 0.84 TBXA2R (0.58) TBXA2RADRA1ASLC6A3HTR1AADRA2A
SCHEMBL3377507 0.84 CYP3A4 (0.61) TBXA2RADRA1ASLC6A3HTR1AADRA2A
SCHEMBL9761425 0.84 TBXA2R (0.59) TBXA2RADRA1ASLC6A3HTR1AADRA2A
SCHEMBL28342101 0.84 TBXA2R (0.60) TBXA2RADRA1ASLC6A3HTR1AADRA2A
SCHEMBL30516331 0.83 CYP3A4 (0.49) TBXA2RADRA1ASLC6A3HTR1AADRA2A
SCHEMBL30516334 0.83 TBXA2R (0.56) TBXA2RADRA1ASLC6A3HTR1AADRA2A
SCHEMBL22105882 0.83 ADORA3 (0.50) TBXA2RADRA1ASLC6A3HTR1AADRA2A
SCHEMBL25377373 0.82 TBXA2R (0.90) TBXA2RADRA1ASLC6A3HTR1AADRA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1814527-B2 BILAYER TABLET COMPRISING TELMISARTAN AND AMLODIPINE BOEHRINGER INGELHEIM INT (DE) 2020-11-18 EP disclosed
US-20200316029-A1 FIXED DOSE COMBINATION OF TELMISARTAN, HYDROCHLOROTHIAZIDE AND AMLODIPINE BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2020-10-08 US disclosed
WO-2017207375-A1 FIXED DOSE COMBINATION OF TELMISARTAN, HYDROCHLOROTHIAZIDE AND AMLODIPINE BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2017-12-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200316029-A1 FIXED DOSE COMBINATION OF TELMISARTAN, HYDROCHLOROTHIAZIDE AND AMLODIPINE ACE, AGT, REN TBXA2R 1229/4885ADRA1A 1987/4885SLC6A3 2702/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.